Stock listing
BSE:MARKSANS Marksans Pharma Limited Share Price
Indian listing (BSE) of Marksans Pharma Limited · home listing NSE:MARKSANS
Follow Marksans Pharma Limited into a list and get an email when it puts out news.
Home listing price · NSE:MARKSANS
₹291.15 INR -3.35 (-1.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NSE:MARKSANS
- Day range
- ₹288.40 – ₹297.20 INRNov 20, 2026
- Volume
- 907,580 sharesNov 20, 2026
- Market cap
- ₹132.0B INRAt the close on Nov 20, 2026 · price × 453.2M shares outstanding
- 52-week range
- ₹155.00 – ₹350.95 INRLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- ₹580.4M INRMedian day 1.46M shares · 3 days with no trades · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NSE:MARKSANS · Home | ₹291.15 INR | -3.35 (-1.1%) | 907,580 | ₹296.00 | ₹297.20 | ₹288.40 | ₹294.50 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NSE:MARKSANS · INR, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| ₹291.15 | -3.35 | -1.1% | ₹296.00 | ₹297.20 | ₹288.40 | 907,580 | |
| ₹294.50 | -11.60 | -3.8% | ₹306.20 | ₹315.55 | ₹291.30 | 1,414,007 | |
| ₹306.10 | -3.10 | -1.0% | ₹307.90 | ₹309.20 | ₹302.00 | 899,969 | |
| ₹309.20 | -9.30 | -2.9% | ₹318.50 | ₹318.90 | ₹307.65 | 1,184,443 | |
| ₹318.50 | -1.50 | -0.5% | ₹323.70 | ₹328.70 | ₹315.50 | 1,738,972 | |
| ₹320.00 | +13.45 | +4.4% | ₹306.00 | ₹322.95 | ₹305.85 | 2,088,557 | |
| ₹306.55 | -2.20 | -0.7% | ₹310.00 | ₹310.45 | ₹303.05 | 1,216,362 | |
| ₹308.75 | +5.05 | +1.7% | ₹305.60 | ₹313.50 | ₹305.20 | 823,630 | |
| ₹303.70 | -10.05 | -3.2% | ₹312.50 | ₹313.00 | ₹301.85 | 1,341,800 | |
| ₹313.75 | +12.10 | +4.0% | ₹307.00 | ₹316.25 | ₹300.35 | 2,103,185 | |
| ₹301.65 | -13.65 | -4.3% | ₹316.90 | ₹327.00 | ₹296.60 | 5,960,208 | |
| ₹315.30 | +3.00 | +1.0% | ₹315.50 | ₹317.95 | ₹312.00 | 786,626 | |
| ₹312.30 | +6.10 | +2.0% | ₹306.90 | ₹314.50 | ₹305.90 | 835,052 | |
| ₹306.20 | -9.15 | -2.9% | ₹317.00 | ₹317.35 | ₹304.90 | 1,208,920 | |
| ₹315.35 | +10.15 | +3.3% | ₹305.90 | ₹318.80 | ₹300.00 | 2,008,651 | |
| ₹305.20 | +5.10 | +1.7% | ₹301.10 | ₹308.25 | ₹298.65 | 1,405,300 | |
| ₹300.10 | +3.45 | +1.2% | ₹297.60 | ₹303.10 | ₹294.80 | 1,026,423 | |
| ₹296.65 | +9.75 | +3.4% | ₹286.90 | ₹298.75 | ₹285.10 | 1,170,447 | |
| ₹286.90 | -7.55 | -2.6% | ₹292.00 | ₹295.35 | ₹282.70 | 1,414,458 | |
| ₹294.45 | -3.70 | -1.2% | ₹294.00 | ₹298.00 | ₹291.25 | 817,786 | |
| ₹298.15 | -4.90 | -1.6% | ₹304.65 | ₹306.75 | ₹293.60 | 1,385,441 | |
| ₹303.05 | -7.95 | -2.6% | ₹311.00 | ₹314.50 | ₹302.00 | 817,392 | |
| ₹311.00 | +3.15 | +1.0% | ₹308.10 | ₹313.50 | ₹306.00 | 767,998 | |
| ₹307.85 | -6.30 | -2.0% | ₹314.20 | ₹315.10 | ₹306.55 | 681,887 | |
| ₹314.15 | -3.10 | -1.0% | ₹315.00 | ₹320.90 | ₹312.35 | 592,331 | |
| ₹317.25 | +0.85 | +0.3% | ₹316.95 | ₹318.00 | ₹309.80 | 1,011,092 | |
| ₹316.40 | +7.30 | +2.4% | ₹310.00 | ₹318.00 | ₹309.00 | 822,584 | |
| ₹309.10 | +1.30 | +0.4% | ₹308.50 | ₹316.40 | ₹308.00 | 1,140,146 | |
| ₹307.80 | -17.65 | -5.4% | ₹326.10 | ₹326.25 | ₹304.45 | 2,348,179 | |
| ₹325.45 | +1.05 | +0.3% | ₹325.80 | ₹329.00 | ₹318.45 | 2,155,353 | |
| ₹324.40 | -7.25 | -2.2% | ₹332.75 | ₹341.95 | ₹322.20 | 3,112,693 | |
| ₹331.65 | +6.05 | +1.9% | ₹327.20 | ₹333.00 | ₹324.60 | 1,566,583 | |
| ₹325.60 | 0.00 | 0.0% | ₹325.60 | ₹325.60 | ₹325.60 | 0 | |
| ₹325.60 | +3.30 | +1.0% | ₹322.05 | ₹332.50 | ₹318.15 | 2,445,782 | |
| ₹322.30 | -20.45 | -6.0% | ₹344.00 | ₹345.90 | ₹321.00 | 3,253,271 | |
| ₹342.75 | +11.20 | +3.4% | ₹333.00 | ₹347.40 | ₹332.95 | 4,594,619 | |
| ₹331.55 | -5.40 | -1.6% | ₹335.40 | ₹341.00 | ₹329.00 | 1,876,478 | |
| ₹336.95 | -0.45 | -0.1% | ₹337.50 | ₹341.95 | ₹331.85 | 1,452,979 | |
| ₹337.40 | -10.20 | -2.9% | ₹345.80 | ₹350.95 | ₹336.15 | 2,858,544 | |
| ₹347.60 | +14.65 | +4.4% | ₹332.95 | ₹348.95 | ₹331.00 | 3,317,178 | |
| ₹332.95 | -5.15 | -1.5% | ₹340.05 | ₹340.95 | ₹328.65 | 1,560,912 | |
| ₹338.10 | +17.95 | +5.6% | ₹322.20 | ₹339.00 | ₹321.20 | 3,189,102 | |
| ₹320.15 | +0.45 | +0.1% | ₹321.35 | ₹325.85 | ₹318.65 | 975,318 | |
| ₹319.70 | +3.25 | +1.0% | ₹315.95 | ₹322.50 | ₹312.95 | 1,104,335 | |
| ₹316.45 | +3.60 | +1.2% | ₹311.80 | ₹323.60 | ₹307.05 | 2,264,075 | |
| ₹312.85 | -16.55 | -5.0% | ₹330.00 | ₹331.40 | ₹301.10 | 2,298,117 | |
| ₹329.40 | 0.00 | 0.0% | ₹329.40 | ₹329.40 | ₹329.40 | 0 | |
| ₹329.40 | -1.00 | -0.3% | ₹325.00 | ₹333.75 | ₹324.20 | 1,631,814 | |
| ₹330.40 | +0.25 | +0.1% | ₹329.00 | ₹334.55 | ₹323.80 | 1,295,256 | |
| ₹330.15 | -5.75 | -1.7% | ₹336.00 | ₹340.00 | ₹328.65 | 1,784,442 | |
| ₹335.90 | +9.15 | +2.8% | ₹337.50 | ₹349.95 | ₹331.60 | 5,090,238 | |
| ₹326.75 | 0.00 | 0.0% | ₹326.75 | ₹326.75 | ₹326.75 | 0 | |
| ₹326.75 | -5.45 | -1.6% | ₹333.00 | ₹335.45 | ₹323.45 | 1,654,370 | |
| ₹332.20 | -0.30 | -0.1% | ₹334.30 | ₹341.00 | ₹331.00 | 2,726,464 | |
| ₹332.50 | +10.10 | +3.1% | ₹321.20 | ₹337.65 | ₹318.75 | 6,573,003 | |
| ₹322.40 | +0.80 | +0.2% | ₹322.90 | ₹324.70 | ₹315.50 | 1,408,843 | |
| ₹321.60 | -8.10 | -2.5% | ₹328.10 | ₹329.90 | ₹313.10 | 2,486,251 | |
| ₹329.70 | +3.55 | +1.1% | ₹326.15 | ₹335.45 | ₹324.05 | 1,463,661 | |
| ₹326.15 | -4.90 | -1.5% | ₹332.00 | ₹332.95 | ₹323.05 | 1,415,329 | |
| ₹331.05 | +12.55 | +3.9% | ₹319.95 | ₹332.40 | ₹319.20 | 1,989,892 | |
| ₹318.50 | -5.40 | -1.7% | ₹326.30 | ₹330.75 | ₹315.10 | 1,686,249 | |
| ₹323.90 | +2.60 | +0.8% | ₹322.60 | ₹325.50 | ₹317.90 | 1,794,290 | |
| ₹321.30 | +0.45 | +0.1% | ₹320.85 | ₹327.00 | ₹313.85 | 2,597,073 | |
| ₹320.85 | -6.15 | -1.9% | ₹328.50 | ₹328.55 | ₹318.50 | 1,960,211 |
Splits
1 split · NSE:MARKSANS · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 10-for-1 | Split |
- Ticker
- BSE:MARKSANS
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- BSE
- Currency
- INR
What changed lately
Latest news release · Nov 4, 2026
Marksans Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release dated 4 November 2026 regarding unaudited financial results for the quarter and half year ended 30 September 2026.".
Latest deck · Nov 4, 2026
Q2 FY27 Earnings Presentation
Earnings · 54 slides
Latest news
Marksans Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release dated 4 November 2026 regarding unaudited financial results for the quarter and half year ended 30 September 2026.".
Nov 4, 2026
Closed ₹301.65 (-4.3%) on Nov 4, 2026
Marksans Pharma Limited Press Release Aug 12 2026
Aug 12, 2026
Closed ₹312.60 (+12.1%) on Aug 12, 2026
Marksans Pharma Limited Press Release Jul 08 2026
Jul 8, 2026
Closed ₹263.45 (+0.9%) on Jul 8, 2026
Press Release Jun 01 2026
May 31, 2026
Closed ₹238.68 (-3.1%) on Jun 1, 2026
Press Release May 26 2026
May 26, 2026
Closed ₹254.79 (+15.7%) on May 26, 2026
Press Release Apr 01 2026
Apr 1, 2026
Closed ₹168.15 (+0.1%) on Apr 2, 2026
Press Release Feb 05 2026
Feb 5, 2026
Closed ₹177.36 (-1.2%) on Feb 6, 2026
Press Release Nov 20 2025
Nov 20, 2025
Closed ₹191.73 (-0.7%) on Nov 21, 2025
Marksans Pharma Limited on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 7 in the last 12 months · 77 in all · newest Nov 4, 2026 · oldest 2020
- Decks
- 33 decks · latest Nov 4, 2026
Where Marksans Pharma Limited is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NSE:MARKSANS · Home listing | NSE | India | INR |
| BSE:MARKSANS · This page | BSE | India | INR |
Valuation
P/E 23.6× against a median of 42.0×: 3rd lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- ₹125.4B INR
- P/E
- 23.6×
- EV/sales
- 3.7×
- EV/EBITDA
- 16.0×
- Price/book
- 4.0×
- Gross margin
- 41.0%
- Operating margin
- 20.0%
- Net margin
- 16.5%
- Debt to equity
- 0.1×
- Beta
- No index for this market yet
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Marksans Pharma Limited · NSE:MARKSANS | US$1.42B | US$1.35B | 23.6× | 3.7× | 16.0× | 4.0× | 16.5% | 0.1× | n/a |
| Yifan Pharmaceutical Co., Ltd. Class A · SZSE:002019 | US$1.52B | US$1.60B | 32.6× | 2.2× | n/a | 1.1× | 6.3% | 0.2× | n/a |
| Precigen, Inc. · NASDAQ:PGEN | US$1.51B | US$1.56B | 61.9× | 9.9× | 40.9× | 18.0× | 15.6% | 1.1× | 1.46 |
| Corona Remedies Limited · NSE:CORONA | US$1.49B | US$1.48B | 74.8× | 9.8× | 46.7× | 17.2× | 13.2% | 0.0× | n/a |
| Sunshine Lake Pharma Co., Ltd. Class H · HKEX:6887 | US$1.48B | US$1.48B | 36.2× | 2.0× | 9.0× | 2.5× | 5.7% | 0.4× | n/a |
| Zhejiang Medicine Co., Ltd. Class A · SSE:600216 | US$1.47B | US$973.2M | 15.5× | 0.8× | n/a | 0.8× | 7.5% | 0.0× | n/a |
| Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675 | US$1.46B | US$1.41B | 46.5× | 3.6× | n/a | 2.2× | 8.0% | 0.1× | n/a |
| Fujian Haixi Pharmaceuticals Co., Ltd. Class H · HKEX:2637 | US$1.45B | US$1.27B | 54.6× | 14.6× | 41.3× | 5.8× | 30.4% | 0.0× | n/a |
| Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A · SZSE:002020 | US$1.40B | US$1.23B | 13.2× | 2.0× | n/a | 1.6× | 17.5% | 0.0× | n/a |
| Chengdu Olymvax Biopharmaceuticals Inc. Class A · SSE:688319 | US$1.37B | US$1.39B | n/a | 11.7× | n/a | 10.2× | −4.0% | 0.4× | n/a |
| Celltrion Pharm Inc. · KRX:068760 | US$1.34B | US$1.25B | 42.0× | 2.9× | 19.6× | 4.0× | 7.4% | 0.0× | n/a |
| Median of the others | US$1.46B | US$1.40B | 42.0× | 3.2× | 40.9× | 3.3× | 7.7% | 0.1× | 1.46 |
Forecasts
Analysts' consensus from EODHD, read Nov 16, 2026. Not 6ix's view and not investment advice.
- Price target
- 322.33 INR · Analysts' mean
- EPS, year to Mar 2027
- 12.70 · 2 analysts
- Revenue, year to Mar 2027
- 36.48B · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Mark Saldanha | Chairman & Managing Director |
Board
| Director | Role |
|---|---|
| Abhinna Sundar Mohanty | Independent Director |
| Digant Mahesh Parikh | Independent Director |
| Sandra Saldanha | Whole-time Director |
| Shailaja Vardhan | Independent Director |
| Srinivas Mishra | Independent Director |
| Sunny Sharma | Non-executive Director |
| Varddhman V. Jain | Whole-time Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q2 2027 | Nov 4, 2026 · Before open | −4.3% |
| Q1 2027 | Aug 12, 2026 · Before open | +12.1% |
| Q4 2026 | May 26, 2026 · Before open | +15.7% |
| Q3 2026 | Feb 5, 2026 · Before open | +1.4% |
| Q3 2024 | Feb 13, 2024 · Before open | +7.8% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q2 FY27 Earnings Presentation | Earnings | 54 slides | Nov 4, 2026 |
| Q1 FY27 Earnings Presentation | Earnings | 51 slides | Aug 12, 2026 |
| Q4 FY26 Earnings Presentation | Earnings | 56 slides | May 26, 2026 |
| Q3 FY2026 Earnings Presentation | Earnings | 48 slides | Feb 5, 2026 |
| Q2 FY26 Earnings Presentation | Earnings | 49 slides | Nov 13, 2025 |
| Q1 FY2026 Earnings Presentation | Earnings | 48 slides | Aug 12, 2025 |
| Q1 FY2026 Earnings Presentation | Earnings | 47 slides | Aug 12, 2025 |
| Q4 FY25 Earnings Presentation | Earnings | 52 slides | May 19, 2025 |
| Q3 FY25 Earnings Presentation | Earnings | 48 slides | Feb 11, 2025 |
| H1 FY25 Earnings Presentation | Earnings | 49 slides | Nov 12, 2024 |
All 33 decks
Financials
Annual, in INR
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 29.5B | 26.2B | 21.8B | 18.5B | 14.8B | 13.7B | 11.3B | 9.87B | 9.13B | 7.67B |
| Cost of revenue | 17.9B | 11.4B | 10.7B | 9.21B | 7.48B | 6.19B | 5.68B | 5.17B | 5.48B | 4.72B |
| Gross profit | 11.6B | 14.8B | 11.0B | 9.31B | 7.32B | 7.50B | 5.61B | 4.70B | 3.65B | 2.95B |
| Research and development | 230.6M | 158.9M | 192.5M | 128.7M | 83.1M | 57.1M | 52.7M | 45.3M | ||
| Selling, general and administrative | 2.87B | 245.7M | 177.0M | 162.6M | 248.0M | 238.8M | 179.7M | 232.0M | 206.3M | 192.0M |
| Operating income | 5.05B | 11.3B | 3.87B | 3.00B | 5.17B | 5.48B | 1.70B | 1.09B | 516.0M | 155.3M |
| Depreciation and amortization | 986.3M | 833.9M | 742.7M | 518.5M | 447.8M | 361.5M | 266.6M | 228.0M | 268.4M | 300.9M |
| EBITDA | 6.03B | 12.1B | 4.62B | 3.52B | 5.62B | 5.84B | 1.97B | 1.32B | 784.4M | 456.2M |
| Interest expense | 241.3M | 116.6M | 112.0M | 91.3M | 84.5M | 79.9M | 87.5M | 96.6M | 102.2M | 67.9M |
| Income before tax | 5.61B | 5.04B | 4.24B | 3.38B | 2.48B | 3.02B | 1.57B | 1.04B | 498.0M | 155.3M |
| Income tax | 1.40B | 1.21B | 1.09B | 723.3M | 607.0M | 636.3M | 364.2M | 238.7M | 140.0M | 35.1M |
| Net income | 4.18B | 3.81B | 3.14B | 2.66B | 1.85B | 2.39B | 1.21B | 804.4M | 329.4M | 95.2M |
| Earnings per share, basic | 9.22 | 8.40 | 6.92 | 6.41 | 4.51 | 5.83 | 2.95 | 1.97 | 0.80 | 0.23 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 6.34B | 4.96B | 4.03B | 3.82B | 3.46B | 2.09B | 931.2M | 328.5M | 397.2M | 251.6M |
| Short-term investments | 3.55B | 2.09B | 2.97B | 3.33B | 1.40B | 17.2M | 17.2M | 500.0K | 897.1K | |
| Receivables | 6.45B | 5.42B | 4.59B | 4.20B | 3.96B | 2.77B | 2.43B | 1.84B | 1.83B | 2.48B |
| Inventory | 9.72B | 8.46B | 6.18B | 4.85B | 4.24B | 4.04B | 2.42B | 2.93B | 2.18B | 1.90B |
| Current assets | 27.2B | 22.0B | 18.6B | 16.8B | 12.0B | 9.02B | 5.90B | 5.31B | 4.49B | 4.84B |
| Property, plant and equipment | 8.95B | 3.87B | 3.42B | 2.54B | 2.30B | 1.98B | 1.86B | 1.65B | ||
| Goodwill | 452.6M | 409.3M | 395.0M | 384.9M | 300.3M | 195.9M | 243.8M | 314.5M | 617.5M | 696.8M |
| Total assets | 38.6B | 32.4B | 26.8B | 21.9B | 16.4B | 12.3B | 8.97B | 8.04B | 7.29B | 7.52B |
| Accounts payable | 3.37B | 3.06B | 2.68B | 2.31B | 2.00B | 1.69B | 1.10B | 1.06B | 674.8M | 1.62B |
| Current liabilities | 5.27B | 4.77B | 3.90B | 3.41B | 3.56B | 2.98B | 2.20B | 2.33B | 2.33B | 3.01B |
| Long-term debt | 0 | 50.0M | 50.0M | 100.0M | 100.0M | 110.0M | ||||
| Total debt | 3.43B | 3.22B | 2.44B | 1.23B | 1.11B | 391.0M | 296.5M | 1.10B | 1.28B | 1.21B |
| Total liabilities | 8.08B | 7.50B | 5.95B | 4.25B | 4.17B | 3.23B | 2.48B | 2.51B | 2.49B | 3.01B |
| Shareholders' equity | 30.2B | 24.7B | 20.7B | 17.5B | 12.0B | 8.86B | 6.36B | 5.42B | 4.71B | 4.45B |
| Shares outstanding | 453.3M | 453.1M | 453.2M | 415.4M | 409.3M | 409.3M | 409.3M | 409.3M | 409.3M | 409.3M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 4.82B | 2.07B | 2.30B | 2.37B | 992.6M | 1.79B | 2.10B | 274.0M | 589.2M | 88.4M |
| Capital spending | -1.31B | -1.73B | -2.09B | -536.3M | -463.3M | -464.2M | -596.3M | -131.5M | -389.4M | -277.5M |
| Free cash flow | 3.51B | 337.4M | 215.7M | 1.84B | 529.3M | 1.32B | 1.50B | 142.5M | 199.9M | -189.1M |
| Cash from investing | -2.75B | -490.1M | -1.41B | -2.59B | -416.9M | -449.0M | -595.8M | -134.8M | -387.8M | -208.4M |
| Cash from financing | -681.4M | -651.5M | -687.3M | 1.98B | 795.1M | -152.9M | -901.5M | -207.8M | -54.3M | 18.6M |
| Dividends paid | -362.5M | -271.9M | -226.6M | -101.7M | -105.8M | -40.9M | -295.0M | -44.4M | -24.6M | -145.3M |
| Share buybacks | 0 | -451.7M | -451.7M | -911.5M | -50.0M | -50.0M | -10.0M | -15.0M | ||
| Change in cash | 4.93B | 925.1M | 208.4M | 1.76B | 1.37B | 1.19B | 602.7M | -68.6M | 147.1M | -101.4M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Marksans Pharma Limited has informed the Exchange regarding a press release dated November 04, 2026, titled "Press release dated 4 November 2026 regarding unaudited financial results for the quarter and half year ended 30 September 2026.". | Nov 4, 2026 | Results | NSE India |
| Marksans Pharma Limited Press Release Aug 12 2026 | Aug 12, 2026 | Results | NSE India |
| Marksans Pharma Limited Press Release Jul 08 2026 | Jul 8, 2026 | Acquisition or disposal | NSE India |
| Press Release Jun 01 2026 | May 31, 2026 | Acquisition or disposal | NSE India |
| Press Release May 26 2026 | May 26, 2026 | Results | NSE India |
| Press Release Apr 01 2026 | Apr 1, 2026 | Operations update | NSE India |
| Press Release Feb 05 2026 | Feb 5, 2026 | Results | NSE India |
| Press Release Nov 20 2025 | Nov 20, 2025 | Other filings | NSE India |
| Press Release Nov 19 2025 | Nov 19, 2025 | Operations update | NSE India |
| Press Release Nov 17 2025 | Nov 17, 2025 | Other filings | NSE India |
All 72 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| Press Release Nov 13 2025 | Nov 13, 2025 | Results | NSE India |
| Press Release Nov 10 2025 | Nov 10, 2025 | Other filings | NSE India |
| Marksans Pharma Limited Press Release Nov 05 2025 | Nov 4, 2025 | Operations update | NSE India |
| Press Release Oct 15 2025 | Oct 15, 2025 | Other filings | NSE India |
| Press Release Sep 23 2025 | Sep 23, 2025 | Other filings | NSE India |
| Press Release Aug 18 2025 | Aug 18, 2025 | Other filings | NSE India |
| Press Release Aug 12 2025 | Aug 12, 2025 | Quarterly report | NSE India |
| Press Release Aug 08 2025 | Aug 8, 2025 | Other filings | NSE India |
| Press Release Jun 30 2025 | Jun 30, 2025 | Other filings | NSE India |
| Marksans Pharma Limited Press Release Jun 19 2025 | Jun 18, 2025 | Other filings | NSE India |
| Marksans Pharma Limited Press Release May 30 2025 | May 29, 2025 | Other filings | NSE India |
| Press Release May 19 2025 | May 19, 2025 | Other filings | NSE India |
| Marksans Pharma Limited Press Release May 15 2025 | May 14, 2025 | Other filings | NSE India |
| Press Release Apr 28 2025 | Apr 28, 2025 | Other filings | NSE India |
| Press Release Mar 20 2025 | Mar 20, 2025 | Operations update | NSE India |
| Press Release Mar 19 2025 | Mar 19, 2025 | Other filings | NSE India |
| Press Release Feb 25 2025 | Feb 25, 2025 | Other filings | NSE India |
| Press Release (Revised) Feb 11 2025 | Feb 11, 2025 | Results | NSE India |
| Press Release Feb 11 2025 | Feb 11, 2025 | Results | NSE India |
| Press Release Nov 22 2024 | Nov 22, 2024 | Operations update | NSE India |
| Press Release Nov 12 2024 | Nov 12, 2024 | Results | NSE India |
| Press Release Aug 21 2024 | Aug 21, 2024 | Operations update | NSE India |
| Press Release Aug 20 2024 | Aug 20, 2024 | Operations update | NSE India |
| Press Release Aug 13 2024 | Aug 13, 2024 | Quarterly report | NSE India |
| Press Release Aug 02 2024 | Aug 2, 2024 | Other filings | NSE India |
| Press Release Jul 02 2024 | Jul 2, 2024 | Operations update | NSE India |
| Press Release May 30 2024 | May 30, 2024 | Results | NSE India |
| Press Release May 28 2024 | May 28, 2024 | Other filings | NSE India |
| Press Release Apr 18 2024 | Apr 18, 2024 | Legal or regulatory action | NSE India |
| Press Release Feb 13 2024 | Feb 13, 2024 | Results | NSE India |
| Press Release Nov 09 2023 | Nov 9, 2023 | Other filings | NSE India |
| Press Release Nov 06 2023 | Nov 6, 2023 | Operations update | NSE India |
| Press Release Nov 03 2023 | Nov 3, 2023 | Other filings | NSE India |
| Press Release Nov 01 2023 | Nov 1, 2023 | Operations update | NSE India |
| Press Release Oct 03 2023 | Oct 3, 2023 | Operations update | NSE India |
| Press Release Aug 22 2023 | Aug 22, 2023 | Operations update | NSE India |
| Press Release Aug 11 2023 | Aug 11, 2023 | Quarterly report | NSE India |
| Press Release Aug 07 2023 | Aug 7, 2023 | Operations update | NSE India |
| Press Release Jul 12 2023 | Jul 12, 2023 | Operations update | NSE India |
| Press Release May 30 2023 | May 30, 2023 | Results | NSE India |
| Press Release Apr 19 2023 | Apr 19, 2023 | Other filings | NSE India |
| Press Release Mar 10 2023 | Mar 10, 2023 | Other filings | NSE India |
| Press Release Feb 13 2023 | Feb 13, 2023 | Other filings | NSE India |
| Press Release Jan 23 2023 | Jan 23, 2023 | Operations update | NSE India |
| Marksans Pharma Limited Press Release Jan 20 2023 | Jan 19, 2023 | Other filings | NSE India |
| Press Release Nov 14 2022 | Nov 14, 2022 | Other filings | NSE India |
| Press Release Oct 11 2022 | Oct 11, 2022 | Other filings | NSE India |
| Press Release Aug 13 2022 | Aug 13, 2022 | Other filings | NSE India |
| Press Release Jul 21 2022 | Jul 21, 2022 | Operations update | NSE India |
| Press Release Jun 21 2022 | Jun 21, 2022 | Other filings | NSE India |
| Press Release Apr 25 2022 | Apr 25, 2022 | Acquisition or disposal | NSE India |
| Press Release Feb 22 2022 | Feb 22, 2022 | Operations update | NSE India |
| Press Release Jan 11 2022 | Jan 11, 2022 | Operations update | NSE India |
| Press Release Dec 09 2021 | Dec 9, 2021 | Operations update | NSE India |
| Press Release Nov 10 2021 | Nov 10, 2021 | Other filings | NSE India |
| Press Release Aug 26 2021 | Aug 26, 2021 | Other filings | NSE India |
| Press Release Aug 11 2021 | Aug 11, 2021 | Other filings | NSE India |
| Press Release Jul 10 2021 | Jul 10, 2021 | Other filings | NSE India |
| Press Release May 31 2021 | May 31, 2021 | Other filings | NSE India |
| Press Release Nov 06 2020 | Nov 6, 2020 | Other filings | NSE India |
| Press Release Oct 03 2020 | Oct 3, 2020 | Other filings | NSE India |
| Press Release Aug 04 2020 | Aug 4, 2020 | Results | NSE India |
Cap table
Built by 6ix from Marksans Pharma Limited’s releases
- Common shares
- 453,219,996
- Fully diluted
- 453,219,996
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 453,219,996 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 453,219,996 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Abhinna Sundar Mohanty | Independent Director · Since at least Nov 4, 2026 |
| Digant Mahesh Parikh | Independent Director · Since at least Nov 4, 2026 |
| Mark Saldanha | Chairman & Managing Director · Since at least Nov 4, 2026 |
| Sandra Saldanha | Whole-time Director · Since at least Nov 4, 2026 |
| Shailaja Vardhan | Independent Director · Since at least Nov 4, 2026 |
| Srinivas Mishra | Independent Director · Since at least Nov 4, 2026 |
| Sunny Sharma | Non-executive Director · Since at least Nov 4, 2026 |
| Varddhman V. Jain | Whole-time Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Marksans Pharma Limited.